Investors

Print
Homepage  >  MEDTOX Info  >  Investors

MEDTOX Scientific, Inc.  Investor Relations 877-715-7236

Basic Industries:  Lab & POC Diagnostic Drug Testing, Clinical Trials, Clinical Toxicology, Lead Screening, Lab Services

NASDAQ Symbol:  MTOX

NASDAQ Fundamentals

MEDTOX Focus:  Building a Business within Laboratory and Diagnostic Testing Markets

LAB DRUG TESTING                 DIAGNOSTIC TESTING                     SPECIALTY LAB TESTING
$500 Million Market*                  Multi-Billion $ Market                         $2 to $2.5 Billion Market*

* MEDTOX estimates


Vital Statistics - Year-End 2007
2007 Revenue: $80.3 Million
2007 EPS: $0.75
Shares Outstanding: 8,434,850
Approximate Public Float: 7,520,000
Insider Ownership: 11%
Institutional Ownership: 59%
Fiscal Year End: December 31

NEWS & INSIGHTS

View UPS Shipping Detail

Attention Clients:  Important change in implementation date for revisions to HHS and DOT workplace drug testing programs.

SAMHSA has postponed the May 1, 2010 implementation of the revised HHS Mandatory Guidelines for Federal Workplace Drug Testing Programs.  The new effective date is October 1, 2010.

The delay was issued to provide sufficient time for the DOT to evaluate comments and issue a final rule harmonizing its regulations with the revised HHS Guidelines in a time frame that will permit implementation of the rules at the same time.  This action is welcomed; it will allow HHS-certified laboratories to use the same testing and reporting procedures for Federal workplace and transportation workplace drug testing programs subject to DOT Regulations, avoid the confusion of administering regulatory programs with different requirements and will ensure fairness in treatment of employees subject to the rules.  

A notice is posted in the Federal Register for publication on April 30, 2010.  The document is available at the Federal Register’s website:  Click Here

Workplace Drug Testing Updates

© 2008 MEDTOX Scientific, Inc. All rights reserved.